Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 7:36 PM
Ignite Modification Date:
2025-12-24 @ 7:36 PM
NCT ID:
NCT01862003
Brief Summary:
Recruitment to phase I of the PANTHER trial is complete.
Phase II, is to evaluate the best overall response rate for AZD8931 + FOLFIRI treatment.
Detailed Description:
PANTHER is a registered phase I/phase II trial in patients with recurrent or metastatic colorectal cancer.
The phase II part of the study will be a single arm trial. Patients will receive AZD8931 (an EGFR/ERBB inhibitor) in combination with FOLinic acid, Fluorouracil and IRInotecan (FOLFIRI), Treatment will be given in two-weekly cycles. Phase II's primary objective is to evaluate the Best overall response
Study:
NCT01862003
Study Brief:
Protocol Section:
NCT01862003